• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sonendo Inc. (Amendment)

    11/13/23 9:31:44 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care
    Get the next $SONX alert in real time by email
    SC 13G/A 1 arrowmark-sonx103123a2.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*



    Sonendo, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    835431107

    (CUSIP Number)

     

     

    October 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No. 835431107
     SCHEDULE 13G
    Page 2 of 6 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    ArrowMark Colorado Holdings, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware, United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    2,068,411
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    2,068,411
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,068,411
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    3.93%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     
     

     

    CUSIP No.  835431107
     SCHEDULE 13G
    Page 3 of 6 Pages

     

    Item 1.(a) Name of Issuer

    Sonendo, Inc.

    (b) Address of Issuer’s Principal Executive Offices

    26061 Merit Circle, Suite 102

    Laguna Hills, CA 92653

    Item 2.(a) Name of Person Filing

    ArrowMark Colorado Holdings, LLC

    (b) Address of Principal Business Office, or, if none, Residence

    100 Fillmore Street, Suite 325

    Denver, Colorado 80206

    (c) Citizenship

    Please refer to Item 4 on each cover sheet for each filing person

     (d) Title of Class of Securities

    Common Stock, par value $0.001 per share

     (e) CUSIP No.:

    835431107

     
     

     

    CUSIP No.  835431107
     SCHEDULE 13G
    Page 4 of 6 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 835431107
     SCHEDULE 13G
    Page 5 of 6 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned: 2,068,411

    (b) Percent of class: 3.93%

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote: 2,068,411

    (ii) Shared power to vote or to direct the vote: 0

    (iii) Sole power to dispose or to direct the disposition of: 2,068,411

    (iv) Shared power to dispose or to direct the disposition of: 0

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

    Item 9. Notice of Dissolution of Group

     

    Not Applicable

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

      

     
     
    CUSIP No. 835431107
     SCHEDULE 13G
    Page 6 of 6 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 13, 2023

     

     

      ArrowMark Colorado Holdings, LLC
           
      By:  Richard Grove
        Name:  Richard Grove
        Title:  Chief Compliance Officer

     

     

     

     

     

     

     

    Get the next $SONX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SONX

    DatePrice TargetRatingAnalyst
    3/12/2024Buy → Hold
    Stifel
    1/31/2022$6.90Equal-Weight
    Morgan Stanley
    11/23/2021$16.00Buy
    Stifel
    11/23/2021$15.00Buy
    B of A Securities
    11/23/2021$30.00Buy
    Goldman Sachs
    11/23/2021$17.00Overweight
    Piper Sandler
    More analyst ratings

    $SONX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. VP Operations Mcgaugh John P. was granted 500,000 shares, increasing direct ownership by 142% to 852,896 units (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    9/19/24 5:48:44 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Bostjancic John J. was granted 600,000 shares, increasing direct ownership by 83% to 1,320,000 units (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    9/19/24 5:46:24 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    President and CEO Bergheim Bjarne was granted 1,600,000 shares, increasing direct ownership by 85% to 3,488,518 units (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    9/19/24 5:42:53 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer

    Sonendo, Inc. ("Sonendo" or the "Company") (OTC:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. "Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn," stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "John has been a significant contributor to all those improvements, and we expect he will continue to

    8/20/25 4:15:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance

    Sonendo, Inc. ("Sonendo" or the "Company"), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the three-months ended June 30, 2025 and reaffirmed 2025 financial guidance. Select Second Quarter Financial Results Generated $7.4 million of total revenue for the second quarter of 2025, an 11% decline compared to the prior year period, which was expected and driven entirely by lower console sales through a smaller and more cost effective sales team; Reported an increase in gross margin to 41% for the second quarter of 2025, up 320 basis points compared to the prior year period; Reported a $3.6 million reduction in

    8/13/25 10:50:00 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial Guidance

    Sonendo, Inc. ("Sonendo" or the "Company") (OTC:SONX), a leading dental technology company and developer of the GentleWave® System, today reported select financial results for the first quarter ended March 31, 2025 and issued short and long-term financial guidance. Recent Highlights Generated $7.4 million of total revenue for the first quarter of 2025, representing 5% growth compared to the prior year period; Drove a substantial increase in gross margin to 44% for the first quarter of 2025, up 1600 basis points compared to the 28% gross margin for the prior year period; Reported a 48% year-over-year improvement in Adjusted EBITDA loss to $3.9 million for the first quarter of 2025

    6/4/25 6:30:00 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Mcgaugh John P. bought $11,545 worth of shares (116,500 units at $0.10), increasing direct ownership by 47% to 363,797 units (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    5/23/24 6:05:19 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Bergheim Olav bought $49,504 worth of shares (520,000 units at $0.10) (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    5/17/24 2:30:11 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Pudipeddi Vamsi Mohan Raj bought $47,000 worth of shares (500,000 units at $0.09), increasing direct ownership by 27% to 2,374,498 units (SEC Form 4)

    4 - Sonendo, Inc. (0001407973) (Issuer)

    5/14/24 5:18:33 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    SEC Filings

    View All

    SEC Form D filed by Sonendo Inc.

    D - Sonendo, Inc. (0001407973) (Filer)

    5/12/25 1:21:37 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Sonendo Inc.

    10-K - Sonendo, Inc. (0001407973) (Filer)

    3/26/25 4:06:45 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Sonendo Inc.

    EFFECT - Sonendo, Inc. (0001407973) (Filer)

    2/28/25 12:15:03 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Financials

    Live finance-specific insights

    View All

    Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024

    Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca

    11/11/24 4:05:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo, Inc. to Report Third Quarter 2024 Financial Results on November 12, 2024

    Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the third quarter 2024 after the market close on Tuesday, November 12th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 788725. Live audio of the webcast will be available at: https://investor.sonendo.com. An archived recording will be available on th

    10/29/24 4:05:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue Guidance

    Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Generated $8.3 million total revenue for second quarter of 2024 and carried over a healthy console backlog for the second straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 37.5% and 40.7%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $6.7 million and adjusted EBITDA (non-GAAP) loss to $5.7 million, a 61% and 55% improv

    8/7/24 4:05:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sonendo downgraded by Stifel

    Stifel downgraded Sonendo from Buy to Hold

    3/12/24 7:33:34 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Morgan Stanley initiated coverage on Sonendo with a new price target

    Morgan Stanley initiated coverage of Sonendo with a rating of Equal-Weight and set a new price target of $6.90

    1/31/22 7:34:46 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on Sonendo with a new price target

    Stifel initiated coverage of Sonendo with a rating of Buy and set a new price target of $16.00

    11/23/21 7:43:50 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sonendo Inc.

    SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

    11/14/24 4:40:34 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sonendo Inc.

    SC 13G - Sonendo, Inc. (0001407973) (Subject)

    11/14/24 1:23:43 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sonendo Inc. (Amendment)

    SC 13G/A - Sonendo, Inc. (0001407973) (Subject)

    2/14/24 5:15:11 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    $SONX
    Leadership Updates

    Live Leadership Updates

    View All

    Sonendo Strengthens Leadership With Key Strategic Appointments

    John Bostjancic Appointed as Chief Financial Officer Bob Guyatt Appointed as Senior Vice President of Marketing John McGaugh Promoted to Senior Vice President of Operations Sonendo, Inc. (OTCQX:SONX) ("Sonendo"), a leading dental technology company and developer of the GentleWave® System, today announced the appointment of John Bostjancic as Chief Financial Officer, the appointment of Robert Guyatt as Senior Vice President of Marketing, and the promotion of John McGaugh to Senior Vice President of Operations. "Sonendo is embarking on a reset strategy to drive fundamental change within the organization," said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "We have fil

    6/5/24 4:05:00 PM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo Announces New Partnership Agreements with Two Leading Specialty DSOs to Expand Access to the GentleWave® Procedure for Elevated Root Canal Treatment

    The Partnership Agreements Aim to Increase the Number of Endodontic Practices Offering the GentleWave System Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the signing of two new strategic partnership agreements with the country's leading endodontic dental service organizations (DSOs) to expand patient access to a best-in-class root canal experience. As a result of these partnerships, the GentleWave System with CleanFlow™ Technology, which offers a less invasive and less painful alternative to traditional root canal therapy, will be available in more endodontic offices nationwide. Sonendo previously announced the a

    10/4/23 8:00:00 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care

    Sonendo, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08

    Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that on September 25, 2023, the Compensation Committee of Sonendo's Board of Directors granted restricted stock unit awards covering an aggregate of 14,000 shares of its common stock to two new, non-executive employees to induce them to join the company. The awards were granted under Sonendo's 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"), which was adopted on March 2, 2023 and provides for the granting of equity awards to prospective employees of Sonendo under NYSE Listing Rule 303A.08. The restricted stock unit awards vest over a four-year p

    9/26/23 8:00:00 AM ET
    $SONX
    Medical/Dental Instruments
    Health Care